333 related articles for article (PubMed ID: 21712241)
1. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
[TBL] [Abstract][Full Text] [Related]
2. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
[TBL] [Abstract][Full Text] [Related]
3. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
4. Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.
Westin MR; Biscione F; Ribeiro KM; Greco DB; Tupinambás U
AIDS Res Hum Retroviruses; 2014 Feb; 30(2):113-7. PubMed ID: 23875625
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
[TBL] [Abstract][Full Text] [Related]
6. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
Boulet T; Pavie J; Charreau I; Braun J; Reynes J; Morlat P; Piroth L; Spire B; Molina JM; Aboulker JP;
HIV Clin Trials; 2010; 11(5):283-93. PubMed ID: 21126958
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.
de Castro N; Braun J; Charreau I; Lafeuillade A; Viard JP; Allavena C; Aboulker JP; Molina JM;
AIDS Res Ther; 2016; 13():17. PubMed ID: 27042193
[TBL] [Abstract][Full Text] [Related]
8. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
[TBL] [Abstract][Full Text] [Related]
9. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.
Silva EF; Charreau I; Gourmel B; Mourah S; Kalidi I; Guillon B; De Castro N; Caron F; Braun J; Molina JM;
J Infect Dis; 2013 Sep; 208(6):892-7. PubMed ID: 23801606
[TBL] [Abstract][Full Text] [Related]
10. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
Harris M; Larsen G; Montaner JS
AIDS; 2008 Jun; 22(10):1224-6. PubMed ID: 18525270
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
14. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
[TBL] [Abstract][Full Text] [Related]
15. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
17. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.
Grant PM; Palmer S; Bendavid E; Talbot A; Slamowitz DC; Cain P; Kobayashi SS; Balamane M; Zolopa AR
J Clin Virol; 2009 Dec; 46(4):305-8. PubMed ID: 19819183
[TBL] [Abstract][Full Text] [Related]
18. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
[TBL] [Abstract][Full Text] [Related]
19. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
